Patents
Escherichia coli strain secreting human granulocyte colony stimulating factor (G-CSF)
Patent Number: 7070989This patent is important for entities seeking to use the hematopoietic stem cell stimulatory/differentiation factor, granulocyte colony stimulating factor (G-CSF) that is produced in E. coli. The patent has 2 independent claims, the first to a vector encoding human G-CSF, and the second to a method of producing human G-CSF.
Inventors: Lee, Sang-Yup (Taejon, KR); Jeong, Ki-Jun (Taejon, KR)
Assignee: Korea Advanced Institute of Science and Technology (KR)
Date of First Priority Issue: Friday March 31st, 2000
Injection devices that provide reduced outflow of therapeutic agents and methods of delivering therapeutic agents
Patent Number: 7070582This patent is a medical device useful for administration of therapeutic agents into a host, through a unique 2 catheter approach that can simultaneously deliver various agents including stem cells. The device if very interesting since it does not require a needle, but includes alternative delivery methods for implatnation of therapeutic solutions and cells into tissue in a localized area.
Inventors: Freyman, Toby (Watertown, MA); Naimark, Wendy (Cambridge, MA); Mickley, Tim (Elk River, MN); Epstein, Samuel J. (Newton, MA)
Assignee: Boston Scientific Scimed, Inc. (Maple Grove, MN)
Date of First Priority Issue: Sunday September 8th, 2002
Hematopoietic stimulation
Patent Number: 7067489The invention is useful for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells which can be used both in vivo and in vitro. It appears that CD26 is a peptidase that cleaves certain proteins, including hematopoietic growth factors. Additionally, CD26 cleaves SDF-1 the chemotactic signal that calls in...
Inventors: Wallner, Barbara P. (Cohasset, MA); Jones, Barry (Cambridge, MA); Miller, Glenn T. (Merrimac, MA); Adams, Sharlene (Waltham, MA)
Assignee: Point Therapeutics, Inc. (Boston, MA)
Date of First Priority Issue: Monday May 4th, 1998
Methods and devices for the long-term culture of hematopoietic progenitor cells
Patent Number: 7067316This patent is useful for the long term, in vitroculture of hematopoietic progenitor cells in the absence of exogenously added hematopoietic growth factors. It appears that the inventors developed a system that replicates the bone marrow structure but does not require addition of cytokines or other growth factors, or serum. The invention has 2 independent claims. The first covers a porous...
Inventors: Pykett, Mark J. (Boxford, MA); Rosenzweig, Michael (Boston, MA); Kaplan, Richard B. (Beverly Hills, CA)
Assignee: Cytomatrix, LLC (Woburn, MA)
Date of First Priority Issue: Thursday September 25th, 1997
Bioartificial device for the storage, cultivation and/or multiplication of cells
Patent Number: 7067307This invention is useful for generating artificial tissue, particularly, but not limited to hepatocytes using a flow-through bioreactor that has the following advantages over the existing technologies: a) Cells can be cultivated; b) Cell growth is under extremely low shear forces and turbulences; c) A continuous supply of oxygen-saturated nutrient medium is provided; and d) Continuous assessment...
Inventors: Hochleitner, Boris-Wolfgang (Graz, AT); Hengster, Paul (Innsbruck, AT)
Assignee: Raimung Margreiter (Seefeld, AT)
Date of First Priority Issue: Saturday November 2nd, 2002
Methods of using mutant flt3-ligand polypeptides to induce cellular expansion
Patent Number: 7067118This invention teaches ways of generating active portions of the stem cell expanding protein flt-3L and using these active portions. The assignee is the same company, (Immunex) that developed the original flt-3L. The patent has 4 independent claims. The first covers expanding stem cells, the second covers in vivo expansion, the third covers transplanting cells and expanding them in vivo, the...
Inventors: Graddis, Thomas J. (Cupertino, CA); McGrew, Jeffrey T. (Seattle, WA)
Assignee: Immunex Corporation (Seattle, WA)
Date of First Priority Issue: Saturday February 7th, 1998
Process for reconstructing a non-human mammalian embryo by nuclear transfer using a heat treated donor nucleus and preparaing a non-human mammal
Patent Number: 7064245One of the issues associated with cloning of animals is that the donor nucleus has to be reprogrammed by the recipient oocyte. Reprogramming involves unraveling of the densely packed DNA chromatin structures which is performed by the oocyte cytoplasmic machinery. In this invention, heat treatment of donor cell or constituents thereof us used to increase the rate of proper reprogramming. The...
Inventors: Loi, Pasqualino (Sassari, IT); Cappai, Pietro (Sassari, IT)
Assignee: Istituto Zootecnico E Caseario per La Sardegna (Sasari, IT)
Date of First Priority Issue: Friday June 4th, 1999
Cytokine zcytor17 ligand
Patent Number: 7064186This is a composition of matter patent covering the cytokine zcytor17 ligand, which is involved in various immune and stem cell activities. The patent has 3 independent claims, all covering composition of matter. The email of the senior author is dillons@zgi.com
Inventors: Sprecher, Cindy A. (Sierra Vista, AZ); Kuijper, Joseph L. (Kenmore, WA); Dasovich, Maria M. (Seattle, WA); Grant, Francis J. (Seattle, WA); Hammond, Angela K. (Kirkland, WA); Novak, Julia E. (Suquamish, WA); Gross, Jane A. (Seattle, WA); Dillon, Stacey R.
Assignee: ZymoGenetics, Inc. (Seattle, WA)
Date of First Priority Issue: Friday January 18th, 2002
Compounds and methods for inhibiting the interaction between .alpha.-catenin and .beta.-catenin
Patent Number: 7063842The catenins are involved in numerous cell to cell interactions. This patent covers ways of inhibiting alpha and beta catenin interactions using a chemical composition. Specifically, the patent has 3 independent claims. The first is for modulating the interaction between alpha and beta catenin with specific peptides and antibodies. The second is for a pharmaceutical composition. The third...
Inventors: Blaschuk, Orest W (Westmount, CA); Gour, Barbara J (Kemptville, CA)
Assignee: McGill University (Montreal, CA)
Date of First Priority Issue: Saturday October 4th, 1997
Growth of human Mesenchymal Stem Cells (hMSC) using umbilical cord blood serum and the method for the preparation thereof
Patent Number: 7060494This patent is useful for expansion and maintaining mesenchymal stem cells through the uniquely discovered property of cord blood serum to be able to substitute for other sources of serum such as fetal calf serum. The patent has 3 independent claims. The first is directed towards growing mesenchymal stem cells, and the second at third are directed towards isolating mesenchymal stem cells by...
Inventor: Bhat, Aravind Venkatrao (Mumnai, IN)
Assignee: Reliance Life Sciences Pvt. Ltd. (Maharashtra, IN)
Date of First Priority Issue: Wednesday September 4th, 2002